Skip to main content
Industry News
Medication "product hopping" costs US billions

A study from Matrix Global Advisors found product hopping, which involves moving patients to reformulated versions of a medication before the patent expires, costs the US health care system billions of dollars a year. The report examined five such instances, pegging the cost of the strategy at $4.7 billion per year for Namenda, Prisolec, TriCor, Doryx and Suboxone.

Full Story: